Skip to main content
Premium Trial:

Request an Annual Quote

BD, Bruker Update Collaboration on Antimicrobial Technologies

NEW YORK (GenomeWeb News) – BD Diagnostics and Bruker are updating a 2010 agreement to include international distribution of the co-labeled BD Bruker Maldi Biotyper system.

The deal covers an integrated microbiology solution that combines the BD Bruker Maldi Biotyper System with the BD Phoenix System and the BD EpiCenter Microbiology Data Management System. The Bruker Maldi Biotyper System is used for the molecular identification and taxonomical classification or dereplication of microorganisms, while the BD Phoenix is an automated microbiology system for automated identification and susceptibility testing.

The deal, announced over the weekend, builds on a 2010 agreement between the companies for the co-development and co-marketing of microbial identification technologies combing the Maldi Biotyper and the BD Phoenix System. According to BD Diagnostics, a segment of Becton Dickinson, the combination of its technologies with Bruker's system is anticipated to reduce the turnaround time required for diagnostic results, while at the same time improve laboratory efficiency and costs. Rather than taking hours, it added, identifying pathogens will now take minutes.

"BD believes mass spectrometry technologies are the future of microbial identification," Jamie Condie, vice president and general manager of BD Diagnostics - Diagnostic Systems, Infectious Disease, said in a statement. "Combining Bruker's expertise in this area with our advanced lab automation experience, the BD Bruker Maldi Biotyper System will enhance our customers' clinical decision making and laboratory workflow."

The Bruker Maldi Biotyper is not yet available in the US for in vitro diagnostic use, Bruker noted.

Financial and other terms of the deal were not disclosed.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.